文献速递炎症性肠病

评估克罗恩病蒙特利尔分类的双向降期版本:前瞻性BioCrohn研究5年随访数据分析

Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-13

研究基于BioCrohn注册的前瞻性起始队列,纳入病程≤12个月的克罗恩病患者并随访5年,评估双向蒙特利尔分类对疾病消退的捕捉能力。393例患者5年并发症累积概率为41.5%,肛周病变和早期肠切除与穿透性并发症风险升高相关。双向分类显示90%患者5年时呈炎症行为,而单向分层分类仅为58%。

要点

  • 5年并发症累积概率41.5%,狭窄15.6%、穿透25.9%。
  • 肛周病变HR 8.45(95%CI 4.74-15.07)与穿透并发症风险升高相关。
  • 双向分类5年炎症行为90%,单向分层分类为58%。

核心结论

  • 额外采用双向疾病行为评估可捕捉逆转或完全控制的并发症,可能更真实反映接受先进治疗患者的复杂性和未满足需求。

研究设计与样本

  • 基于BioCrohn注册的前瞻性起始队列,纳入病程≤12个月的克罗恩病患者并随访5年,共393例,其中255例完成全部随访。
  • 采用Kaplan-Meier法估计并发症累积概率,Cox回归估计解释变量与疾病进展的关联。

主要发现

  • 393例患者5年并发症累积概率为41.5%,其中狭窄并发症15.6%、穿透并发症25.9%。
  • 疾病极早期肛周病变与5年随访内穿透并发症风险升高相关,HR 8.45(95%CI 4.74-15.07)。
  • 疾病极早期肠切除手术与5年随访内穿透并发症风险升高相关,HR 2.71(95%CI 1.50-4.92)。
  • 双向蒙特利尔分类显示90%患者5年时呈炎症性疾病行为,而单向分层蒙特利尔分类为58%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Under the assumption of irreversibility, the Montreal classification provides a unidirectional assessment of the complications and behaviour of Crohn's disease (CD) that does not allow for downstaging. We examined the use of a bidirectional Montreal classification system that can capture disease regression. DESIGN: From the BioCrohn Registry, an inception cohort of patients with CD for ≤12 months duration was defined and followed up for 5-years. Cumulative probabilities for developing complications were estimated using the Kaplan-Meier method. Potential associations of explanatory variables with disease progression were estimated with Cox regression. RESULTS: Among 393 incident CD patients (of whom 255 completed the entire follow-up), the 5-year cumulative probability of developing complications was 41.5% (15.6% and 25.9% for stricturing and penetrating complications respectively). Perianal disease (hazard ratio [95% confidence interval]: 8.45 [4.74-15.07]) and surgical resection of the intestine (2.71 [1.50-4.92]) in the very early phase of the disease were associated with a higher risk of developing a penetrating complication within the 5-year follow-up. The use of a bidirectional Montreal classification system which can account for disease regression demonstrated that 90% of patients exhibited inflammatory disease behaviour at 5 years, in contrast to 58%, if the hierarchical, unidirectional Montreal classification system was used. CONCLUSION: An additional bidirectional disease behaviour assessment capturing reversed or fully controlled complications may provide a more realistic appraisal of the complexity and unmet needs of patients treated with advanced therapies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, et al. Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study. Aliment Pharmacol Ther. 2023. PMID: 37051808. doi:10.1111/apt.17512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。